Logo des Robert Koch-InstitutLogo des Robert Koch-Institut
Publikationsserver des Robert Koch-Institutsedoc
de|en
Publikation anzeigen 
  • edoc Startseite
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • Publikation anzeigen
  • edoc Startseite
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • Publikation anzeigen
JavaScript is disabled for your browser. Some features of this site may not work without it.
Gesamter edoc-ServerBereiche & SammlungenTitelAutorSchlagwortDiese SammlungTitelAutorSchlagwort
PublizierenEinloggenRegistrierenHilfe
StatistikNutzungsstatistik
Gesamter edoc-ServerBereiche & SammlungenTitelAutorSchlagwortDiese SammlungTitelAutorSchlagwort
PublizierenEinloggenRegistrierenHilfe
StatistikNutzungsstatistik
Publikation anzeigen 
  • edoc Startseite
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • Publikation anzeigen
  • edoc Startseite
  • Artikel in Fachzeitschriften
  • Artikel in Fachzeitschriften
  • Publikation anzeigen
2011-09-14Zeitschriftenartikel DOI: 10.1093/infdis/jir613
Influenza B Virus With Modified Hemagglutinin Cleavage Site as a Novel Attenuated Live Vaccine
Stech, Jürgen
Garn, Holger
Herwig, Astrid
Stech, Olga
Dauber, Bianca
Wolff, Thorsten
Mettenleiter, Thomas C.
Klenk, Hans-Dieter
Background: Both pandemic and interpandemic influenza is associated with high morbidity and mortality worldwide. Seasonal epidemics are caused by both influenza A and B virus strains that cocirculate with varying predominance and may give rise to severe illness equally. According to World Health Organization recommendations, current annual vaccines are composed of 2 type A and 1 type B virus-specific component. Methods: As a novel attenuated live vaccine against influenza B virus, we generated a hemagglutinin cleavage site mutant of strain B/Lee/40 by replacing the common monobasic cleavage site recognized by trypsinlike proteases with an elastase-sensitive site, and we investigated the in vitro properties, attenuation, humoral responses, and efficacy in mice. Results. This mutant virus replicated in cell culture equally well as the wild type but in a strictly elastase-dependent manner. In contrast to the mouse-pathogenic parental virus, the cleavage site mutant was fully attenuated in mice and not detectable in their lungs. After 1 intranasal immunization, the animals survived lethal challenge with wild-type virus without weight loss or any other signs of disease. Furthermore, no challenge virus could be reisolated from the lungs of vaccinated mice. Conclusions: These findings demonstrate that proteolytic activation mutants can serve as live vaccine against influenza B virus.
Dateien zu dieser Publikation
Thumbnail
234KNNat9yV3U.pdf — PDF — 1.305 Mb
MD5: 0a04a6581b7361c766b679385186cb18
Zitieren
BibTeX
EndNote
RIS
Keine Lizenzangabe
Zur Langanzeige

Verwandte Publikationen

Anzeige der Publikationen mit ähnlichem Titel, Autor, Urheber und Thema.

  • 2016-10-13Zeitschriftenartikel
    Improving influenza virological surveillance in Europe: strain-based reporting of antigenic and genetic characterisation data, 11 European countries, influenza season 2013/14 
    Broberg, E.; Hungnes, Olav; Schweiger, Brunhilde; Prosenc, Katarina; Daniels, R.; Guiomar, R.; Ikonen, N.; Kossyvakis, A.; Pozo, Francisco; Puzelli, S.; Thomas, I.; Waters, A.; Wiman, Å.; Meijer, Adam
    Influenza antigenic and genetic characterisation data are crucial for influenza vaccine composition decision making. Previously, aggregate data were reported to the European Centre for Disease Prevention and Control by ...
  • 2011-03-16Zeitschriftenartikel
    Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene 
    Soprana, Elisa; Panigada, Maddalena; Knauf, Mathias; Radaelli, Antonia; Vigevani, Luisa; Palini, Alessio; Villa, Chiara; Malnati, Mauro; Cassina, Giulia; Kurth, Reinhard; Norley, Stephen; Siccardi, Antonio G.
    Pairs of recombinant MVA (Modified Vaccinia Ankara) and FPV (Fowlpox Virus) expressing the same transgene are reasonable candidates for prime/boost regimens, because cross-reacting immune responses between the two vectors, ...
  • 2015-04-28Zeitschriftenartikel
    The European I-MOVE Multicentre 2013–2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2) 
    Valenciano, Marta; Kissling, Esther; Reuss, Annicka; Jiménez-Jorge, Silvia; Horváth, Judit K.; Donnell, Joan M.O.; Pitigoi, Daniela; Machado, Ausenda; Pozo, Francisco
    Background: In the first five I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) influenza seasons vaccine effectiveness (VE) results were relatively homogenous among participating study sites. In 2013–2014, ...
Nutzungsbedingungen Impressum Leitlinien Datenschutzerklärung Kontakt

Das Robert Koch-Institut ist ein Bundesinstitut im

Geschäftsbereich des Bundesministeriums für Gesundheit

© Robert Koch Institut

Alle Rechte vorbehalten, soweit nicht ausdrücklich anders vermerkt.

 
DOI
10.1093/infdis/jir613
Permanent URL
https://doi.org/10.1093/infdis/jir613
HTML
<a href="https://doi.org/10.1093/infdis/jir613">https://doi.org/10.1093/infdis/jir613</a>